Mesco Pharmaceuticals has informed that pursuant to Regulation 29 read with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, the meeting of the Board of Directors of the Company will be held on Monday, 14th August, 2017 to consider and approve Unaudited Financial Results pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 for the quarter ended 30th June, 2017. As per the Company’s Code of Conduct for Prevention of Insider Trading, framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation 2015, the Trading Window for dealing/trading in the securities of the Company will be closed for the purpose of declaration of Unaudited financial results of the Company for the quarter ended 30th June, 2017 for all the Designated Employees, Directors and key managerial personnel of the Company from August 8, 2017 till 48 hours after the announcement of the financial results of the Company to the Stock Exchange.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1528.20 |
Dr. Reddys Lab | 5872.35 |
Cipla | 1405.95 |
Zydus Lifesciences | 997.45 |
Lupin | 1638.40 |
View more.. |